Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

When putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics LENZ now meets that criteria, with a jump from 79 to 85 Friday. Please watch the video at ...

The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

LENZ Therapeutics' LNZ100 leads presbyopia treatment with superior efficacy and FDA approval likely by Aug. 2025. Learn more ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz ...

LENZ Therapeutics continues to make strong progress in its U.S. commercial preparations for LNZ100, its investigational treatment for presbyopia, as the Company approaches the August 8, 2025 PDUFA ...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 Provided by GlobeNewswire Mar 11, 2025, 12:00:00 PM ...

LENZ Therapeutics’ product candidate addresses a widespread condition affecting approximately 1.8 billion people globally, highlighting the potential market size and opportunity for the company.